PE20091008A1 - Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa - Google Patents
Derivados heterociclicos como moduladores de fosfoinositida 3-cinasaInfo
- Publication number
- PE20091008A1 PE20091008A1 PE2008001296A PE2008001296A PE20091008A1 PE 20091008 A1 PE20091008 A1 PE 20091008A1 PE 2008001296 A PE2008001296 A PE 2008001296A PE 2008001296 A PE2008001296 A PE 2008001296A PE 20091008 A1 PE20091008 A1 PE 20091008A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phosphoinositide
- modulators
- kinase
- benzothiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE A1 ES CR3 O N; A2 ES CR4 O N; A3 ES CR5 O N; A4 ES CR6 O N; X ES OXIGENO O S; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R2 ES ALQUILO C1-C6-R7a, ALQUENILO C2-C6-R7a, ALQUINILO C2-C6-R7a, ENTRE OTROS; R3, R4, R5 Y R6 SON H, HALO, ALQUILO C1-C8, ENTRE OTROS; R7a ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(6-(2-(3-(3-PIRIDINIL)PROPOXI)-4-PIRIMIDINIL)-1,3-BENZOTIAZOL-2-IL)ACETAMIDA, N-(6-(2-(3-MORFOLINO)PROPOXI)-4-PIRIMIDINIL)-1,3-BENZOTIAZOL-2-IL)ACETAMIDA, N-(6-(2-(3-PIRIDINIL)ETOXI)-4-PIRIMIDINIL)-1,3-BENZOTIAZOL-2-IL)ACETAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DE LA FOSFOINOSITIDA 3-CINASA (PI3K) Y SON UTILES EN EL TRATAMIENTO DE CARCINOMAS, LEUCEMIAS, GLIOBLASTOMAS, CANCER, ENTRE OTRAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96326307P | 2007-08-02 | 2007-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091008A1 true PE20091008A1 (es) | 2009-08-10 |
Family
ID=39811462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001296A PE20091008A1 (es) | 2007-08-02 | 2008-08-01 | Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa |
Country Status (11)
Country | Link |
---|---|
US (1) | US7928140B2 (es) |
EP (1) | EP2183232B1 (es) |
JP (1) | JP5561702B2 (es) |
AR (1) | AR068051A1 (es) |
AU (1) | AU2008282728B2 (es) |
CA (1) | CA2694136C (es) |
CL (1) | CL2008002294A1 (es) |
ES (1) | ES2401557T3 (es) |
PE (1) | PE20091008A1 (es) |
TW (1) | TW200911798A (es) |
WO (1) | WO2009017822A2 (es) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
JP5520831B2 (ja) | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
AR071523A1 (es) * | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
US20110178070A1 (en) * | 2008-06-24 | 2011-07-21 | Takeda Pharmaceutical Company Limited | PI3K/mTOR INHIBITORS |
AU2010250055A1 (en) | 2009-02-27 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
WO2010100144A1 (en) * | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
WO2010108074A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
TW201103943A (en) | 2009-04-27 | 2011-02-01 | Shionogi & Co | Urea derivative having pi3k inhibitory activity |
CA2760791C (en) * | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
ES2459468T3 (es) | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
US8765747B2 (en) * | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
EP2501678B1 (en) * | 2009-11-17 | 2015-09-23 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
JP5894980B2 (ja) * | 2010-05-24 | 2016-03-30 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
US10414760B2 (en) | 2016-11-29 | 2019-09-17 | Angion Biomedica Corp. | Cytochrome P450 inhibitors and uses thereof |
US8513291B2 (en) | 2010-06-01 | 2013-08-20 | Angion Biomedica Corp. | Cytochrome P450 inhibitors and uses thereof |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
DE102010033690A1 (de) * | 2010-08-06 | 2012-02-09 | Saltigo Gmbh | Verfahren zur Herstellung vom Aminoarylalkylverbindungen |
TWI410425B (zh) | 2010-12-03 | 2013-10-01 | Lilly Co Eli | 唑并[5,4-b]吡啶-5-基化合物 |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
EP2782570B1 (en) * | 2011-11-21 | 2019-09-18 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
TW201332988A (zh) * | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
MX362896B (es) | 2013-02-19 | 2019-02-22 | Amgen Inc | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |
WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
WO2014177915A1 (en) | 2013-05-01 | 2014-11-06 | Piramal Enterprises Limited | Cancer combination therapy using imidazo[4,5-c]quinoline derivatives |
CN104177346A (zh) * | 2013-05-21 | 2014-12-03 | 苏州科捷生物医药有限公司 | 喹唑啉类化合物及其用途 |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
DK3068393T5 (da) | 2013-11-11 | 2022-08-22 | Amgen Inc | Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer |
AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015089481A2 (en) | 2013-12-13 | 2015-06-18 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
CN104860900A (zh) * | 2014-02-25 | 2015-08-26 | 中国药科大学 | 噻唑类化合物、其制备方法及其在制药中的用途 |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
CN105272933B (zh) * | 2014-07-24 | 2017-09-12 | 张皓 | 5‑萘基‑2‑氨基‑苯并[d]噁唑衍生物及其制备方法和用途 |
AU2015300825B2 (en) | 2014-08-07 | 2019-10-10 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
AU2015301891B2 (en) | 2014-08-11 | 2019-12-05 | Angion Biomedica Corporation | Cytochrome P450 inhibitors and uses thereof |
EP3715346B1 (en) | 2014-10-22 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
CN105884711A (zh) * | 2014-12-16 | 2016-08-24 | 中国药科大学 | 噻唑类化合物、其制备方法及其在制药中的用途 |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN104402875A (zh) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途 |
AU2015374231B2 (en) | 2014-12-31 | 2020-07-23 | Angion Biomedica Corp. | Methods and agents for treating disease |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
CN108601767A (zh) | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法 |
WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
JOP20190052A1 (ar) * | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
CN106905258A (zh) * | 2016-12-20 | 2017-06-30 | 上海昕盛医药科技有限公司 | 一种普拉克索杂质b的合成方法 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
PT3692023T (pt) | 2017-10-02 | 2023-08-23 | 1St Biotherapeutics Inc | Compostos de benzotiazol e métodos que os utilizam para tratar distúrbios neurodegenerativos |
AU2018378935A1 (en) | 2017-12-07 | 2020-06-25 | The Regents Of The University Of Michigan | NSD family inhibitors and methods of treatment therewith |
TWI796596B (zh) | 2018-02-13 | 2023-03-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
AU2019262589B2 (en) | 2018-05-04 | 2022-07-07 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
WO2020170206A1 (en) | 2019-02-22 | 2020-08-27 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders |
US10385046B1 (en) | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
AU2020246313B2 (en) | 2019-03-22 | 2022-08-04 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
SG11202112855WA (en) | 2019-05-21 | 2021-12-30 | Amgen Inc | Solid state forms |
WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
WO2021126816A1 (en) | 2019-12-16 | 2021-06-24 | Amgen Inc. | Dosing regimen of a kras g12c inhibitor |
MX2023003631A (es) | 2020-09-28 | 2023-04-11 | 1St Biotherapeutics Inc | Indazoles a manera de inhibidores de cinasa 1 progenitora hematopoyetica (hpk1) y metodos de uso de los mismos. |
WO2023083330A1 (zh) * | 2021-11-12 | 2023-05-19 | 百极优棠(广东)医药科技有限公司 | Drak2抑制剂及其制备方法和应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH505543A (de) * | 1968-11-01 | 1971-04-15 | Ciba Geigy Ag | Schädlingsbekämpfungsmittel |
IL151045A0 (en) | 2000-02-07 | 2003-04-10 | Abbott Gmbh & Co Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
CN100387576C (zh) * | 2002-02-21 | 2008-05-14 | 旭化成制药株式会社 | 取代苯基链烷酸衍生物及其用途 |
AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
EP1620413A2 (en) * | 2003-04-30 | 2006-02-01 | Cytokinetics, Inc. | Compounds, compositions, and methods |
GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
KR20050071115A (ko) * | 2003-12-31 | 2005-07-07 | 동부아남반도체 주식회사 | 반도체 제조 공정에서 에칭 얼룩 제거방법 |
US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
ZA200702435B (en) | 2004-10-12 | 2008-06-25 | Serono Lab | PI3 Kinase gamma inhibitors for the treatment of anaemia |
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US7473784B2 (en) * | 2005-08-01 | 2009-01-06 | Bristol-Myers Squibb Company | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
EP2016068A1 (en) | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Pyrazole derivatives and their use as pi3k inhibitors |
CN101484452A (zh) | 2006-05-03 | 2009-07-15 | 阿斯利康(瑞典)有限公司 | 噻唑衍生物及其作为抗肿瘤药物的用途 |
JP2009537621A (ja) | 2006-05-22 | 2009-10-29 | アストラゼネカ アクチボラグ | インドール誘導体 |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
RU2009106722A (ru) | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
SG174086A1 (en) | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
WO2008052733A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
AU2008250328A1 (en) | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as PI3K lipid kinase inhibitors |
AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
US8131310B2 (en) | 2007-05-18 | 2012-03-06 | Research In Motion Limited | Method and system for discontinuous reception de-synchronization detection |
EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
WO2008152387A1 (en) | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Quinazoline derivatives as pi3 kinase inhibitors |
UY31137A1 (es) | 2007-06-14 | 2009-01-05 | Smithkline Beecham Corp | Derivados de quinazolina como inhibidores de la pi3 quinasa |
US20100210644A1 (en) | 2007-06-25 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Chemical compounds |
KR20100049073A (ko) | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
JP2011500823A (ja) | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
-
2008
- 2008-08-01 TW TW097129367A patent/TW200911798A/zh unknown
- 2008-08-01 US US12/221,416 patent/US7928140B2/en active Active
- 2008-08-01 AU AU2008282728A patent/AU2008282728B2/en active Active
- 2008-08-01 PE PE2008001296A patent/PE20091008A1/es not_active Application Discontinuation
- 2008-08-01 JP JP2010519941A patent/JP5561702B2/ja active Active
- 2008-08-01 WO PCT/US2008/009312 patent/WO2009017822A2/en active Application Filing
- 2008-08-01 CA CA2694136A patent/CA2694136C/en active Active
- 2008-08-01 ES ES08794970T patent/ES2401557T3/es active Active
- 2008-08-01 EP EP08794970A patent/EP2183232B1/en active Active
- 2008-08-04 AR ARP080103383A patent/AR068051A1/es not_active Application Discontinuation
- 2008-08-04 CL CL2008002294A patent/CL2008002294A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008282728B2 (en) | 2012-04-19 |
EP2183232B1 (en) | 2013-03-06 |
TW200911798A (en) | 2009-03-16 |
ES2401557T3 (es) | 2013-04-22 |
US20090054405A1 (en) | 2009-02-26 |
AR068051A1 (es) | 2009-11-04 |
CA2694136C (en) | 2013-09-17 |
CL2008002294A1 (es) | 2009-07-24 |
EP2183232A2 (en) | 2010-05-12 |
JP5561702B2 (ja) | 2014-07-30 |
WO2009017822A2 (en) | 2009-02-05 |
US7928140B2 (en) | 2011-04-19 |
CA2694136A1 (en) | 2009-02-05 |
AU2008282728A1 (en) | 2009-02-05 |
JP2010535216A (ja) | 2010-11-18 |
WO2009017822A3 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091008A1 (es) | Derivados heterociclicos como moduladores de fosfoinositida 3-cinasa | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
PE20091527A1 (es) | Derivados de piridazinona | |
PE20011259A1 (es) | Derivado de piridina y pirimidina | |
PE20090773A1 (es) | Derivados de morfolina pirimidina | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
PE20070946A1 (es) | COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4) | |
AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
PE20090511A1 (es) | Imidazopiridinonas | |
AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
PE20090546A1 (es) | Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5 | |
PE20060623A1 (es) | Compuestos de sulfonamida como potenciadores del receptor de glutamato | |
PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
TW200745117A (en) | Macrocylic inhibitors of hepatitis C virus | |
TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
CY1110952T1 (el) | Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3 | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
NI201000011A (es) | Derivados de pirimidina 934. | |
PE20120002A1 (es) | Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2 | |
PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |